- €16.94m
- €14.34m
- €11.03m
- 65
- 53
- 21
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 0.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.54 | ||
| EV to EBITDA | 29.4 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.1% | ||
| Return on Equity | -3.14% | ||
| Operating Margin | -9.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 26.01 | 19.93 | 17.65 | 8.91 | 11.03 | n/a | n/a | -14.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +2309.53 | +63.39 | +14.77 | -82.15 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biotika as is a Slovakia-based joint stock company that specializes in biotechnology and production of pharmaceutical. The Company's activities are grouped into three main areas: biotechnological production of the substances of penicillin, chlorotetracycline and dextrans; production of final drug-forms for both human and veterinary use, including: penicillin and cephalosporin preparations, hormonal preparations, vitamin preparations; as well as production of premixes containing nutrition additives and medicated nutritive preparations. As of December 31, 2011, the Company operated two wholly owned subsidiaries, COV as Slovenska Lupca and Biotkika KLF as Slovenska Lupca.
Directors
- Maria Kincesova CSU
- Emil Drlicka CMG (64)
- Petrus Winkelman VSU
- Milan Mocik FID (61)
- Denisa Chramcova GCN
- Andrea Lilkova DSL
- Viera Druskova OTH
- Jana Eervenakova OTH
- Slavomir Geleta OTH (53)
- Maria Jakubcova OTH (61)
- Peter Slobodnik OTH
- Miroslava Vargova MGB (57)
- Jozef Debnarik SUB
- Peter Draskovic SUB
- Jozef Trangos SUB
- Dagmar Vargova SUB
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- May 1st, 1992
- Public Since
- November 19th, 1993
- No. of Employees
- 198
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Bratislava Stock Exchange- Shares in Issue
- 700,000
- Address
- Slovenska Lupca 566, SLOVENSKA LUPCA, 976 13
- Web
- https://www.biotika.sk/
- Phone
- +421 484368111
- Auditors
- BDR, spol. s r.o. Banska Bystrica
Upcoming Events for 1BSL01AE
Similar to 1BSL01AE
Zentiva as
Bratislava Stock Exchange
FAQ
As of Today at 19:04 UTC, shares in Biotika as are trading at €45.00. This share price information is delayed by 15 minutes.
Shares in Biotika as last closed at €45.00 and the price had moved by +5.22% over the past 365 days. In terms of relative price strength the Biotika as share price has underperformed the FTSE Global All Cap Index by -1.22% over the past year.
There is no consensus recommendation for this security.
Biotika as does not currently pay a dividend.
Biotika as does not currently pay a dividend.
Biotika as does not currently pay a dividend.
To buy shares in Biotika as you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €45.00, shares in Biotika as had a market capitalisation of €16.94m.
Here are the trading details for Biotika as:
- Country of listing: Slovakia
- Exchange: BRA
- Ticker Symbol: 1BSL01AE
Based on an overall assessment of its quality, value and momentum Biotika as is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotika as. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -6.02%.
As of the last closing price of €45.00, shares in Biotika as were trading -20.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biotika as PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €45.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biotika as' management team is headed by:
- Maria Kincesova - CSU
- Emil Drlicka - CMG
- Petrus Winkelman - VSU
- Milan Mocik - FID
- Denisa Chramcova - GCN
- Andrea Lilkova - DSL
- Viera Druskova - OTH
- Jana Eervenakova - OTH
- Slavomir Geleta - OTH
- Maria Jakubcova - OTH
- Peter Slobodnik - OTH
- Miroslava Vargova - MGB
- Jozef Debnarik - SUB
- Peter Draskovic - SUB
- Jozef Trangos - SUB
- Dagmar Vargova - SUB